Quotient Sciences, Acesion Pharma Partner on AI Drug Formulation
Image
Nottingham, England – October 02, 2026 -- Quotient Sciences and Copenhagen-based Acesion Pharma have launched a collaboration to apply AI-enhanced formulation development to Acesion's early-stage pipeline of small molecules targeting atrial fibrillation, a condition affecting an estimated 50-60 million people globally.
AI tool uses Bayesian optimization to screen drug formulations for clinical success
The collaboration deploys Quotient Sciences' new AI-enhanced formulation development solution within its Translational Pharmaceutics platform, applying active machine learning with Bayesian optimization to identify and prioritize drug products most likely to succeed in clinical testing. The approach is designed to compress early clinical decision-making timelines for sponsors developing new treatments.